Radar · Clinical Genomics in United States
Best Clinical Genomics Companies in United States
The 776 best Clinical Genomics companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Caris Life Sciences.
By Riya SenguptaFinancials
776companies tracked
$19.7Bdisclosed funding
2unicorns
456have raised
The 776 Clinical Genomics companies tracked here across the United States are ranked by disclosed equity funding and recent funding momentum, and the numbers behind this sector are worth sitting with. Total disclosed funding clears $19.7 billion. Two unicorns. Guardant Health alone has pulled $557 million in disclosed capital, with Delfi Diagnostics at $332 million and Alamar Biosciences at $250 million not far behind. That's a meaningful concentration at the top, and it tells you where conviction has been running hardest.
So what's actually driving the money? Hereditary disease genomics, cell-based therapies, and gene delivery systems are the themes attracting the most attention right now, with institutional backers like NIH, HHS, and Casdin Capital among the most active in the field. As shown in 2017 research, the genomic data infrastructure underpinning clinical applications has matured considerably, which partly explains why coverage keeps rising. I'd also flag that automation is reshaping how labs scale, as this recent analysis lays out. Regulatory pressure on diagnostic validation remains a real variable, but the funding trajectory here suggests the sector isn't waiting around for clarity.
Ranked: Best Clinical Genomics companies in United States
| # | Company | Disclosed funding | Last round | Employees | Stage | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | Public | — | 7 signals ▼22% Earnings · IPO | — | — |
| 2 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | Public | Amirali Talasaz Co-founder and Co-Chief Executive Officer | 25 signals ▲56% Earnings · Announcements · Regulatory | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 3 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | Series B | Victor Velculescu Founder and Board of Directors | — | 52 patents Non-invasive cancer detection and monitoring via cell‑free DNA fragmentation profiling | 1 job opening · 1 partnership · 3 awards |
| 4 | Karius Provider of diagnostics for identifying infectious diseases using microbial DNA | $315M | 25 mo ago | 139 139 → 212 (+53%) · sector median +24% | Series C | Tim Blauwkamp Chief Scientific Officer | — | 81 patents Rapid metagenomic sequencing workflows for pathogen detection and microbial biomarker analysis. | — |
| 5 | Alamar Biosciences Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels 67News top 18%Funding top 19%Growth top 30%Moat top 31% All 9 signals ▾Newstop 18% Fundingtop 19% Growthtop 30% Moattop 31% Talenttop 35% Techtop 37% Markettop 44% Fin. healthbottom 46% Globalbottom 36% News: 15 BI events in 12 mo (of 30 tracked, 5 types) · +67% YoY Funding: Raised $250M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $250M | 5 mo ago | 83 | Public | Steve Chen Co-Founder | 15 signals ▲67% IPO · Funding · Leadership | — | 1 internship · 1 launch · 1 expansion |
| 6 | Scipher Medicine Provider of precision medicine based on liquid biopsy test | $231M | 25 mo ago | 126 | Series D | Joseph Loscalzo Co-Founder | — | 29 patents AI-driven personalized therapy monitoring and response prediction for anti‑TNF treatments | — |
| 7 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 21 mo ago | 54 54 → 75 (+39%) · sector median +24% | Series E | Jonathan Romanowsky Co-Founder and Chief Business Officer | — | 52 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 8 | Genome Medical Provider of clinical and DTC genomic testing services | $173M | 21 mo ago | 84 84 → 74 (-12%) · sector median +24% | Series D | — | — | — | — |
| 9 | Clear Labs Provider of food safety technologies for the identification of pathogens 60Patents top 19%Funding top 22%Innovation top 28%Moat top 28% All 10 signals ▾Patentstop 19% Fundingtop 22% Innovationtop 28% Moattop 28% Growthtop 32% Talenttop 41% Globalbottom 44% Marketbottom 40% Techbottom 33% Newsbottom 21% Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $141M | 18 mo ago | 55 55 → 85 (+55%) · sector median +24% | Series D | Sasan Amini Co-Founder & CEO | — | 79 patents Automated liquid handling and cartridge systems for nucleic‑acid sequencing sample preparation | — |
| 10 | Exai Bio Developer of RNA biomarkers and AI platform for cancer detection | $138M | 21 mo ago | 47 | Series B | Babak Alipanahi Co-Founder & Chief Scientific Officer | — | — | 1 job opening · 1 launch · 1 partnership |
| 11 | Strata Oncology Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms | $133M | 19 mo ago | 125 | Series C | Scott Tomlins Co-Founder | — | 19 patents AI-driven genomic biomarkers for predicting cancer therapy and immune checkpoint efficacy | — |
| 12 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 12 mo ago | 54 54 → 61 (+13%) · sector median +24% | Series C | Joseph Victor President & CEO | — | 266 patents Advanced fluorescence microscopy and spectral imaging hardware for multiplexed cellular analysis | 1 launch |
| 13 | Geneoscopy Developer of non-invasive biomarker tests for colorectal cancer | $114M | 17 mo ago | 61 | Series C | — | — | 14 patents Non‑invasive stool‑based nucleic‑acid diagnostics for IBD and colorectal cancer detection | 1 internship · 1 launch · 2 partnerships |
| 14 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 12 mo ago | 33 | Acquired | David Walt Co-Founder | — | 5 patents Remote health monitoring systems that detect critical vitals and trigger emergency interventions | — |
| 15 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Series A | Manish Agarwal Co-Founder | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 16 | Foresight Diagnostics Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 22 mo ago | 35 | Acquired | Ash Alizadeh Co-Founder | — | — | — |
| 17 | Cleveland Diagnostics Developer of diagnostics technology to detect cancer in early stage 53Funding top 21%Moat top 31%Growth top 35%Tech top 39% All 8 signals ▾Fundingtop 21% Moattop 31% Growthtop 35% Techtop 39% Talentbottom 49% Globalbottom 37% Marketbottom 36% Newsbottom 22% Funding: Raised $96.8M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $97M | 8 mo ago | 40 | Series E | Arnon Chait President And Ceo | — | — | 1 award |
| 18 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 9 mo ago | 85 85 → 60 (-29%) · sector median +24% | Public | — | — | — | 2 partnerships |
| 19 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | Public | — | 4 signals ▼33% Earnings · Funding · Leadership | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 20 | ChromaCode Digital molecular biology analytics for disease management | $91M | 16 mo ago | 46 | Series C | — | — | 42 patents Multiplexed digital PCR for nucleic acid and cfDNA analysis in diagnostics | — |
| 21 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 11 mo ago | 35 35 → 41 (+17%) · sector median +24% | Series B | Mads Melbye Co-Founder | — | 49 patents Non‑invasive prenatal diagnostics via methylation and RNA biomarkers for pregnancy monitoring | — |
| 22 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | Series A | Zhiping Weng Co-Founder | — | — | — |
| 23 | Xilis Developer of drug discovery and precision therapy platform for oncology 53Patents top 21%Moat top 21%Innovation top 22%Funding top 26% All 9 signals ▾Patentstop 21% Moattop 21% Innovationtop 22% Fundingtop 26% Talentbottom 49% Marketbottom 46% Globalbottom 42% Techbottom 29% Newsbottom 22% Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $89M | 14 mo ago | 72 | Series B | Hans Clevers Co-Founder | — | 97 patents Micro-organosphere generation, manipulation, and drug testing via advanced microfluidic platforms | — |
| 24 | Personalis Provider of genomic sequencing and diagnosis software for the healthcare industry | $87M | 17 mo ago | 310 310 → 402 (+30%) · sector median +24% | Public | Atul B Co-founder and Scientific Advisor | 5 signals ▼50% Earnings · Announcements | 83 patents Clinical genomics data analysis pipelines for cancer, mosaicism, methylation and multi-species NGS | — |
| 25 | Exicure developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology | $72M | 19 mo ago | 13 13 → 7 (-46%) · sector median +24% | Public | — | — | 41 patents Liposomal spherical nucleic acid delivery systems for immunotherapy and gene‑silencing | — |
| 26 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Series D | Dave Mullarkey Chief Executive Officer | — | — | — |
| 27 | Naveris Provider of blood tests for early cancer detection | $69M | 24 mo ago | 53 | Acquired | Piyush Gupta Founder & CEO | — | — | — |
| 28 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | 25 25 → 31 (+24%) · sector median +24% | Series B | Irene Yuan Co-Founder & Executive Vice President | — | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 29 | Xcell Biosciences Developer of cell culture analysis device for cancer research | $40M | 18 mo ago | 11 11 → 17 (+55%) · sector median +24% | Series B | — | — | 30 patents Advanced cell culture bioreactors for tumor microenvironment phenotypic modulation | — |
| 30 | Affinity Biosensors Developer of rapid antimicrobial susceptibility testing devices for life sciences 27Funding top 27%Moat top 31%Talent bottom 49%Patents bottom 46% All 7 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Patentsbottom 46% Innovationbottom 39% Globalbottom 36% Marketbottom 34% Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $31M | 2 mo ago | 21 | Series B | Ken Babcock CEO | — | 12 patents Rapid antimicrobial susceptibility testing via resonant mass and microchannel sensor technologies | — |
| 31 | Kiyatec Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to… 32Product top 25%Moat top 32%Funding top 37%Innovation top 48% All 9 signals ▾Producttop 25% Moattop 32% Fundingtop 37% Innovationtop 48% Patentstop 50% Marketbottom 40% Globalbottom 37% Techbottom 36% Newsbottom 21% Product: 5 distinct product lines · Company stage: Series C Moat: Editorial + unicorn rating 7/10 · IP moat: 36 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $29M | 7 mo ago | 28 | Series C | — | — | 36 patents In vitro cancer drug screening platforms using 3D tumor bioreactors for dosing optimization | — |
| 32 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 10 mo ago | 7 | Funding Raised | — | — | 26 patents Biosensor and imaging technologies for rapid medical analyte detection and diagnostics | — |
| 33 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 6 mo ago | 9 | Series A | Jarret Glasscock Chief Executive Officer | — | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 34 | DiamiR Developer of minimally invasive diagnostic tests | $22M | 13 mo ago | 13 | Funding Raised | — | — | 24 patents miRNA biomarker assays for diagnosing and monitoring neurodegenerative disorders | — |
| 35 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | Series B | Rodrigo Navarro Co-Founder & CEO & President | — | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 2 partnerships |
| 36 | CrossLife Technologies Innovating molecular diagnostics for better health and saving lives | $16M | 11 mo ago | 6 | Funding Raised | HyunDae Cho Founder & CEO | — | — | — |
| 37 | OncoCyte Developer of non-invasive diagnostic tests solutions for the treatment of cancer | $15M | 16 mo ago | 76 | Public | Ron Andrews CEO & President | — | 40 patents Patents concentrated in chemistry & materials | — |
| 38 | Jan Biotech Provider of diagnostic assays for the detection of infectious diseases 10Funding top 42%Talent bottom 45%Tech bottom 34%Global bottom 29% All 5 signals ▾Fundingtop 42% Talentbottom 45% Techbottom 34% Globalbottom 29% Marketbottom 14% Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $13M | 9 mo ago | 6 | Funding Raised | Jennifer Nichols President/Co-Founder | — | — | — |
| 39 | Alida Biosciences Provider of technology for RNA analysis to improve human health | $12M | 15 mo ago | 16 | Series A | Byron Purse Co-Founder | — | — | 1 internship |
| 40 | Instadiagnostics Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions | $11M | 12 mo ago | 5 | Funding Raised | Johann deSa Founder | — | — | — |
| 41 | Jbs-science Provider of circulating cell-free DNA (cfDNA) for cancer screening | $10M | 14 mo ago | — | Funding Raised | Frank Song Founder | — | — | — |
| 42 | Inherent Biosciences Developer of epigenetic diagnostics and therapeutics for complex diseases | $9M | 14 mo ago | 15 | Series A | Kristin Brogaard Co-Founder & CSO | — | — | — |
| 43 | Aptamatrix Developer of next generation technology based diagnostic tools | $9M | 14 mo ago | 6 | Funding Raised | Philip Borer Co-Founder & President | — | — | — |
| 44 | NovaScan Developer of diagnostic platform technology for cancer detection 32Innovation top 26%Patents top 26%Moat top 32%Funding top 36% All 8 signals ▾Innovationtop 26% Patentstop 26% Moattop 32% Fundingtop 36% Talentbottom 49% Globalbottom 40% Marketbottom 24% Techbottom 24% Innovation: 57 patents (top 28% of patent-holders) · 40 filings since 2022 vs 17 in 2017-21 Patents: 57 patents matched (strict assignee match) · 40 filings since 2022 vs 17 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $8M | 1 mo ago | 16 | Series B | Craig Davis President and CEO | — | 57 patents Intraoperative cancer detection and tissue characterization via impedance-based medical devices | — |
| 45 | KromaTiD Provider of molecular and genetic tests for detection of disease-causing mutations | $7M | 11 mo ago | 31 | Series C | — | 4 signals Funding | 12 patents Cytogenetic kits and methods for chromosome stability and genotoxicity assessment | 1 internship |
| 46 | Gregor Diagnostics Provider of non-invasive screening test for prostate cancer | $7M | 7 mo ago | 12 | Series A | Steven Weinstein CEO | — | — | — |
| 47 | Arima Genomics Developer of technologies for genome sequence and structure | $7M | 11 mo ago | 48 | Series C | — | — | 29 patents Patents concentrated in chemistry & materials | 1 partnership · 1 award |
| 48 | Microsensor Labs Developer of lab-on-chip diagnostic technology for cancer and HAI | $5M | 8 mo ago | — | Funding Raised | Peng Paul Liu President and CEO | — | 14 patents Automated microbial detection, cell sorting, and hygiene compliance monitoring systems | — |
| 49 | Armonica Technologies Developer of long-read DNA sequencing technology for precision medicine | $4M | 7 mo ago | 5 | Series B | — | — | — | — |
| 50 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | Public | — | 9 signals ▲29% Earnings · Capital raise · Announcements | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
Top 12 Clinical Genomics companies in United States
#1
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 48.8% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#2
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#3
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#4
Public · Fremont, California · founded 2018 · 83 employees$250Mraised▾
Public · Fremont, California · founded 2018 · 83 employees
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
News
top 18%Funding
top 19%Growth
top 30%Moat
top 31%Talent
top 35%Tech
top 37%News: 15 BI events in 12 mo (of 30 tracked, 5 types) · +67% YoY · 11 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $250M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Jan 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 30k LinkedIn followers — 5.4% of this cohort's audience · 44 engagements/post (3.2× cohort median)
Activity (LinkedIn): 1 product launches · 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series C$50M
- Feb 2024Series C$100M
- Sep 2021Series B$80M
- Jul 2020Grant (prize money)$321.9K
Founders & team
Investors
Sands Capital, Sherpa Healthcare Partners, Morningside, Samsara BioCapital, Qiming Venture Partners, Illumina Ventures
Tech stack
Apple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCookieyesCore-Js
#5
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Series B · Baltimore, Maryland · founded 2019 · 197 employees
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Patents
top 24%AI
top 28%Moat
top 28%Innovation
top 32%Talent
top 42%Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Conventional Debt (Dec 2025)
Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
AI: Holds AI/ML patents (G06N-family CPC) · Product described with: artificial intelligence
Audience (LinkedIn): 20k LinkedIn followers — 3.5% of this cohort's audience · 29 engagements/post (2.1× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Data Scientist, Computational Biology
Activity (LinkedIn): 1 partnerships · 3 awards (incl. OSF HealthCare) announced in 12 mo
Funding rounds
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
Founders & team
Investors
Merck Global Health Innovation Fund, DFJ Growth, Lilly, Point72, Brown Advisory, Point Field Partners
#6
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#7
Public · Irving, Texas · founded 1996 · 1339 employees$1.1Braised▾
Public · Irving, Texas · founded 1996 · 1339 employees
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Moat
top 15%Funding
top 17%Product
top 19%Market
top 28%Innovation
top 38%Growth
top 40%Moat: Editorial + unicorn rating 9/10 · Unicorn
Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series D (Apr 2025)
Product: 3 distinct product lines · Company stage: Public
Funding rounds
- Apr 2025Series D$168M
- Jan 2023Conventional Debt—
- May 2021Series D$830M
- Oct 2020Conventional Debt$75M
Investors
Coatue, Highland Capital Management, Orbimed, T. Rowe Price, Millennium Management, Neuberger Berman
Tech stack
BootstrapCart FunctionalityCloudflareCloudflare Bot ManagementCookieyesElementor
#8
Series B · Santa Barbara, California · founded 2006 · 21 employees$31.3Mraised▾
Series B · Santa Barbara, California · founded 2006 · 21 employees
Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Patents
bottom 46%Innovation
bottom 39%Global
bottom 36%Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Mar 2026Post IPO$2.3M
- Nov 2024Series B$14.4M
- Jun 2024Series A$3.7M
- Nov 2023Series A$2.4M
Founders & team
Investors
National Science Foundation
#9
Series B · Boston, Massachusetts · founded 2016 · 10 employees$17.1Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 10 employees
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 31%Funding
top 37%Moat
top 38%Innovation
top 41%Tech
bottom 38%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 · Latest publication 2025
Funding: Raised $17.1M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (May 2026)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. VCTS) announced in 12 mo
Funding rounds
- May 2026Series B—
- May 2023Series B$13M
- Jul 2020Series A$4.1M
Founders & team
Tech stack
AosAzureBootstrapCdnjsCloudflareCookieyes
#10
Series E · Cleveland, Ohio · founded 2013 · 40 employees$96.8Mraised▾
Series E · Cleveland, Ohio · founded 2013 · 40 employees
ClevelandDx has developed diagnostics technology to detect cancer in early-stage. The company uses specific biomarkers to distinguish the non-cancerous and cancerous conditions. The expression of these biomarkers is based on a proprietary technology that separates protein isoforms, based on structure.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 21%Moat
top 31%Growth
top 35%Tech
top 39%Talent
bottom 49%Global
bottom 37%Funding: Raised $96.8M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Series E (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series E$14.4M
- Jan 2024Series E$75M
- Feb 2021Series D$19.4M
- Nov 2016Conventional Debt—
Founders & team
Investors
LYFE Capital, Cleveland Clinic, Novo Holdings, Jumpstart, Merchavia Holdings and Investments, Serial Stage Venture Partners
Tech stack
AngularCloudflareCloudflare Bot ManagementCore-JsDocusignDropbox
#11
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Public · Austin, Texas · founded 1993 · 85 employees
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 29%Tech
top 46%Market
bottom 46%Fin. health
bottom 36%Growth
bottom 35%Global
bottom 30%Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) · Last round Post IPO (Sep 2025)
Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Hsts
Market: 85 employees (top 40% of Genomics) · Revenue ~$9.2M · Top-10,000,000 web property
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Chelton Clinic) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
Tech stack
Apple Icloud MailBeaver BuilderCloudflareCore-JsDocusignFacebook Login
#12
Series B · Milwaukee, Wisconsin · founded 2001 · 16 employees$8.1Mraised▾
Series B · Milwaukee, Wisconsin · founded 2001 · 16 employees
Developer of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Innovation
top 26%Patents
top 26%Moat
top 32%Funding
top 36%Talent
bottom 49%Global
bottom 40%Innovation: 57 patents (top 28% of patent-holders) · 40 filings since 2022 vs 17 in 2017-21
Patents: 57 patents matched (strict assignee match) · 40 filings since 2022 vs 17 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 5/10 · IP moat: 57 patents
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Nov 2021Series B$8M
- Sep 2020Seed$100K
- Jul 2017Seed$50K
- Jan 2011Grant (prize money)$1.1M
Founders & team
Investors
Builders VC, Gore Range Capital, ChinaBio Partnering Forum, Dipalo Ventures, HBS Alumni Angels Chicago, Stateline Angels
Funding & investor landscape
$19.7Btotal disclosed funding
430companies funded
1,902disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Dave Mullarkey
Chief Executive Officer · ClearNote Health
Steve Chen
Co-Founder · Alamar Biosciences
Yuling Luo
Co-Founder & CEO · Alamar Biosciences
Victor Velculescu
Founder and Board of Directors · Delfi Diagnostics
Susan Tousi
CEO · Delfi Diagnostics
Ken Babcock
CEO · Affinity Biosensors
Rodrigo Navarro
Co-Founder & CEO & President · 4D Path
Supratim Ray
Co-Founder & CIO · 4D Path
Prism market signals · United States · country-scoped Prism corpus, 4,182 docs
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
RESEARCH SIGNALS · United States
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 53% → 57% across 2008–2026.
top research entities
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
leading researchers
Gerald J. Kost · Liya Xu · Charlotte A. Gaydos · Andrew A. Davis · Yu‐Hsiang Hsieh · Stephanie N. Shishido · Helen J. Huang · David T. Wong
▲
Breakthroughs1,879 · 22%
▲ 18%→24% share
▲1.3× share momentum1 median citations56% since 2021mostly methods-led
Liquid biopsy breakthroughs are surging — U.S. diagnostics papers tripled from 125 to 427, now anchoring 24% field-share.
rising sub-themes (early→recent)
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→58 · Coronavirus disease 2019 (COVID-19) 0→45 · Methylation 0→33
Landmark Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells · 1,071 cites
◆
Advancements3,687 · 43%
▲ 39%→45% share
▲1.2× share momentum2 median citations54% since 2021mostly empirical
Cancer advancement research is intensifying — liquid biopsy advancements nearly quadrupled (183->739), with precision oncology newly emerging.
rising sub-themes (early→recent)
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
Newly emergingTranscriptome 0→19 · Glioblastoma 0→18 · Precision oncology 0→16
Landmark Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies · 5,005 cites
▼
Concerns2,138 · 25%
▼ 32%→22% share
▼0.7× share momentum7 median citations45% since 2021mostly empirical
Concern-flagged diagnostics research is cooling in share (32%->22%) despite liquid biopsy concerns nearly quadrupling to 239 papers.
rising sub-themes (early→recent)
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→40 · Extracellular vesicles 0→21 · Glioma 0→11
Landmark Point-of-Care Diagnostics for Global Health · 1,066 cites
RESEARCH HOTSPOTS · United States
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston642 · +0.40
New York419 · +0.36
SF Bay Area370 · +0.36
Los Angeles278 · +0.50
Philadelphia194 · +0.30
Chicago182 · +0.40
Seattle166 · +0.34
San Diego165 · +0.43
Atlanta127 · +0.28
Ann Arbor108 · +0.47
PATENT SIGNAL · United States
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Washington University ST Louis; annual filings 13→55.
418 filings196 assigneespeak 67/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Detect42
- UNIV Leland Stanford Junior33
- Washington University ST Louis20
- UNIV California19
- Nuclein19
- Texas A & M UNIV SYS19
- New England Biolabs18
- Tempus LABS18
Common questions
How many Clinical Genomics companies are there in United States?
Radar tracks 776 indexable Clinical Genomics companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Clinical Genomics companies in United States?
The Clinical Genomics companies in United States on this list have raised a combined $19.7B in disclosed equity funding across 430 funded companies.
Which is the highest-funded Clinical Genomics company in United States?
Caris Life Sciences is the highest-funded Clinical Genomics company in United States, with $1.1B in disclosed equity funding.
How many Clinical Genomics companies in United States are funded?
430 of the 776 Clinical Genomics companies in United States on this list have disclosed at least one equity funding round.
How many Clinical Genomics unicorns are there in United States?
2 Clinical Genomics companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Clinical Genomics companies?
The most active investors in United States Clinical Genomics companies on this list include HHS, NIH, National Science Foundation, Casdin Capital, Foresite Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.